

1

2

3

4 The effectiveness of early diagnostic tools for neural lesions in leprosy

5 **An observational cohort study**

6

7

8

9 Luciano Henrique Vieira Cegana^{1¶*#a}, Susilene Maria Tonelli Nardi^{2&*#b}, Luciana
10 Pascoeto^{3&}, Vania Del Arco Paschoal^{4&}

11

12 1 Department of Physical Therapy and Public Health, Municipal Health Office, Public
13 Service, Votuporanga, São Paulo, Brazil

14

15 2 Department of Biomedical Sciences, Adolfo Lutz Institute, Health Center, São José do
16 Rio Preto, São Paulo, Brazil.

17

18 3 Department of Physical Therapy and Public Health, Specialized Physical Rehabilitation
19 Center – CER II, Public Service, São José do Rio Preto, São Paulo, Brazil

20

21 4 Department of Nursing and Public Health, Medical School of São José do Rio Preto –
22 FAMERP, Medical School, São José do Rio Preto, São Paulo, Brazil

23

24

25 * Corresponding author

26 E-mail: lucegana@gmail.com (LHVC)

27 E-mail: susilenenardi@gmail.com (SMTN)

28 **ABSTRACT**

29 Cegana LHV, Nardi SMT, Pascoeto L, Paschoal VDA. The effectiveness of early diagnostic
30 tools for neural lesions in leprosy. 33p. MANUSCRIPT– PLOS NTDs Neglected Tropical
31 Diseases, 2020.

32

33 **Introduction:** Leprosy can cause different lesions in peripheral nerves and innervatory
34 structures. **Objectives:** To analyse the effectiveness of evaluation protocols used to identify
35 neural lesions in leprosy such as Degree of Physical Disability (DPD), Simplified
36 Neurological Assessment (SNA), and Neurodynamic Assessment (NDA). **Method:**
37 Descriptive analytical study, associative, with 27 individuals treated in two outpatient leprosy
38 clinics in São Paulo State, between 2017 and 2019, and 27 individuals from the paired control
39 group. The Mann-Whitney, Multivariate Linear Regression and association between
40 variables and $P < 0.05$ values were used. **Results:** The test that most captured the neurological
41 alterations was the SNA, with 22 (81.5%) in the upper limbs (ULs) and 25 (92.6%) in the
42 lower limbs (LLs), followed by the NDA, with 20 (74.1%) in the ULs and 11 (40.7%) in the
43 LLs. The DPD showed handicap in the hands of 16 (59.2%) individuals and in the feet of 17
44 (62.9%) individuals, and they have expressed sensitivity. DPD showed agreement with SNA
45 in 21 (77.8%) of the cases in ULs ($p=0.010$) and 19 (70,4%) of the cases in LLs ($p=0.060$).
46 DPD and NDA showed that in 19 (70.4%) of the patients evaluated there was concordance
47 of results in ULs ($p=0.143$); 9 (33.3%) in LLs ($p=0.125$). SNA and the NDA in the ULs found
48 agreement in 21 (77.8%); 11 (40.7%) ($p=0.786$) in the LLs. **Conclusion:** The three
49 assessment instruments are specific and will hardly produce false positive tests. DPD can
50 produce more false negatives than SNA. If there is an instrument to be chosen, it should be
51 the SNA, since it is more sensitive, more accurate and has a less negative likelihood ratio.
52 Neurodynamic tests were positive in 7.4% of individuals while there were still no changes in
53 the SNA; afterwards, these changes appeared.

54 **Descriptors:** Neural mobilization; Leprosy; Peripheral nerves; Disability; Pain; Physical
55 therapy.

56 INTRODUCTION

57 Among infectious diseases, leprosy is considered one of the main causes of physical
58 disabilities, due to its potential to cause neural injuries^[1].

59 Worldwide, 208,619 new cases of the disease were reported to the World Health
60 Organization (WHO) in 2018, 30,957 occurred in the Americas region and 28,660 (92.6% of
61 the total from the Americas) were reported in Brazil. New cases, which were assessed for its
62 Degree of Physical Disability (DPD), totaled 86.5% (n=24,780); 2,109 (8.5%) had visible
63 physical deformities (DPD 2)^[2].

64 The lack of new diagnostic tools and new drugs, limited knowledge about strategic
65 areas of transmission and unsatisfactory tools for managing the complications caused by
66 leprosy have been an obstacle to its control. Therefore, more coordinated research efforts are
67 still needed^[3].

68 The diagnosis of leprosy is based on the presence of at least one of three cardinal
69 signs: a) lesion(s) and/or area(s) of the skin with changes in thermal and/or pain and/or tactile
70 sensitivity; or b) thickening of the nerve trunks of the peripheral nerves in the upper and
71 lower limbs, associated with sensitivity and/or motor changes in extremities, with decreased
72 muscle strength in the myotomes supplied by these and/or autonomic nerves; or c) presence
73 of *Mycobacterium leprae* bacilli, confirmed by intradermal smear microscopy or skin
74 biopsy^[4].

75 Sometimes neurological involvement is preponderant when compared to a
76 dermatological condition not very significant^[5]. The most affected nerves are the ulnar in the
77 elbow and the fibular in the head of the fibula, followed by the ulnar sensory, superficial and
78 sural fibular branches^[6].

79 In daily practice, a greater occurrence of sensory changes over motor changes is
80 found, as well as a slight presence of deformities^[7]. The sensory and motor actions of

81 *M.leprae* in the upper and lower limbs cause secondary injuries such as fingers^[8] and toes
82 in flexion and “fallen hands and foot”^[9].

83 Although the prevalence of leprosy is decreasing, cases that no longer have the active
84 disease, but which present neurological sequelae, continue to be monitored in health
85 services^[10]. Leprosy reactions are one of the main causes of the onset of disabilities^[11]. It is
86 essential to assess the integrity of neural function at the time of diagnosis, in the occurrence
87 of reactive states, at discharge due to cure (end of multidrug therapy) and during 5 years after
88 discharge^[7].

89 Peripheral neuropathies in leprosy are a triggering factor for physical disabilities, and
90 some evaluation protocols can be used for their prevention, such as the Degree of Physical
91 Disability of the World Health Organization (DPD) and the Simplified Neurological
92 Assessment (SNA) of the Brazilian Ministry of Health^[12]. The routine protocols
93 recommended by the Brazilian Ministry of Health are subjective and, in view of that, other
94 tests could complement the diagnostic examination of peripheral neuropathy such as the
95 Neurodynamic Assessment (NDA)^[7].

96 The DPD is an epidemiological indicator, not very sensitive, but it can define the
97 severity of neurological changes. The SNA assesses muscular strength and sensitivity of
98 eyes, hands and feet, in addition to the palpation of the possibly affected nerves and the
99 morphological evaluation of the limbs^[7].

100 The Neurodynamic Assessment (NDA) is used for injury diagnosis and treatment of
101 the peripheral nervous system and the structures innervated by it^[13]; the interface between
102 the musculoskeletal system and the peripheral nervous system is used, so the movements
103 applied to the musculoskeletal system mobilize the structures of the peripheral nervous
104 system^[14].

105 The use of neurodynamic tests has helped in the diagnosis of neural lesions to identify
106 the origin of the lesions, but little is known about the results of the neurodynamic tests applied
107 to patients with leprosy. Thus, we suggest using the mobilization of the nervous system in
108 clinical practice as a tool to assess peripheral nerves that may be affected by leprosy.

109 **OBJECTIVES**

110 Analyzing the effectiveness of the evaluation protocols used to identify neural lesions
111 in leprosy, such as the Degree of Physical Disability (DPD) recommended by the World
112 Health Organization, the Simplified Neurological Assessment (SNA) and the Neurodynamic
113 Assessment (NDA)

114 Describing the sociodemographic and clinical variables of the groups studied and
115 check whether there is a statistical association between the results of the evaluation tools: the
116 Degree of Physical Disability recommended by the World Health Organization (DPD), the
117 Simplified Neurological Assessment (SNA) and the positive Neurodynamic Assessment
118 (NDA) in individuals who have or had leprosy, in addition to determining the specificity and
119 sensitivity of each of the assessment protocols.

120 **METHODS**

121 Associative, analytical, descriptive research approved by the FAMERP Ethics and
122 Research Committee in accordance with the requirements of National Resolution No. 196/96,
123 Opinion No. 2,469,355. Participants were asked to sign the Informed Consent Form in
124 accordance with Ordinance No. 466/2012.

125 The study included 27 leprosy patients of both sexes and different ages, diagnosed
126 between 2017 and 2019 in one medium (50 to 100 thousand inhabitants) and one large
127 (100,001 to 900,000 inhabitants) Brazilian municipality (Votuporanga and São José do Rio
128 Preto), under treatment or undergoing chemotherapy. A control group of 27 people, chosen
129 from the population, without a diagnosis of leprosy, was evaluated pairing age and sex, thus
130 totaling 54 people. Data collection went from December 2017 to November 2019, until three
131 evaluations were completed.

132 We selected as exclusion criterion for both groups those with compressive syndromes
133 of the central nervous system (CNS) and the peripheral nervous system, other diseases of the
134 CNS such as stroke (stroke) or degenerative syndromes, diabetics and alcoholics with altered
135 sensitivity and people/patients who refused to sign the informed consent form.

136 Initially, a patient profile data sheet, extracted from their medical records, was used,
137 with the name, address, age, sex, date of the beginning of treatment, date of discharge, clinical
138 classification of leprosy and type of treatment. In the control group, name, address, age, sex
139 and existing morbidities were used. Evaluation instruments were applied:

140 • **Simplified Neurological Assessment (SNA)** is a protocol recommended by the
141 Brazilian Ministry of Health, and it contemplates dermatoneurological exploration, the
142 evaluation of eyes, hands and feet sensitivity, and the evaluation of the motor function^[15]. In
143 this clinical examination, the integrity of the skin and its nutrition are assessed. It is
144 recommended to use the Semmes-Weinstein monofilament set (6 monofilaments: 0.05g,

145 0.2g, 2g, 4g, 10g and 300g) in the sensitivity assessment points in hands (palmar surface and
146 back of the hand) and feet (plantar surface and instep near the hallux and the second toe)^[15].
147 To assess motor strength, it is recommended to perform manual testing of muscle strength in
148 the muscle tendon unit during movement and the ability to oppose gravity and manual
149 resistance in each muscle group from a specific nerve (ulnar, median, radial, fibular, posterior
150 tibial myotomes). The grading criteria for muscle strength can be expressed from 0 to 5
151 following the Kendall scale for the degree of muscle strength^[15].

152 • **WHO Degree of Physical Disability (DPD)** varies between Degree 0, I or II
153 according to the severity of sensory and/or motor and/or morphological changes caused by
154 neural lesions of leprosy^[15].

155 • **Neurodynamic tests:** straight leg raises (SLR), Slump Test and upper limb tension
156 tests (ULTT) 1, 2b and 3^[16].

157 1. The straight-leg raise test (SLR) is performed with the patient in the supine
158 position, with the trunk and hips in neutral positions. The examiner places one hand under
159 the Achilles tendon and the other above the knee. The hip is flexed with the knee held in
160 extension until it reveals a predetermined symptomatic response, or until it reaches its hip
161 range of motion (ROM) limit. The range of motion value should be compared to the SLR of
162 the contralateral limb, and to what is considered as normal. If pain, especially lower back
163 pain, is reported during the test, the most likely cause is a herniated disc or a central pathology
164 causing compression. The normal value of SLR in normal individuals varies from 50° to
165 120°^[16].

166 2. The Slump Test should be performed with the patient seated, with the thighs fully
167 supported, the knees together and the hands together on the back. The patient is asked to flex
168 the thoracic and lumbar spine, keeping the sacrum in a vertical position and, soon after, also
169 perform cervical flexion. The physiotherapist puts pressure on the cervical region in order to

170 accentuate flexion. Then, the patient performs an active knee extension, associated with
171 dorsal flexion of the ankle. Cervical flexion is slowly released, and the painful response must
172 be carefully evaluated. The symptoms must be noted at each stage and must also be
173 performed for the other member. ROM and painful responses should be assessed^[16].

174 3. The upper limb tension test (ULTT1) (median neural tension) is described as a
175 brachial plexus tension test or a median nerve test. It is performed with the patient in the
176 supine position. The examiner exerts force to depress the scapular waist, which has an
177 external rotation and 110° abduction of the glenohumeral articulation, elbow extension,
178 radioulnar supination and wrist and fingers extension, the inclination of the cervical to the
179 opposite side was suppressed in our assessment to isolate core involvements. ULTT1 tests
180 are considered positive if present: complaint at deep elongation or pain in the cubital fossa
181 that extends down the anterior and radial part of the forearm and to the radial side of the
182 hand; tingling sensation in the first four fingers; stretching in the anterior shoulder area^[16].

183 4. The upper limb tension tests (ULTT 2b) assess the radial nerve with the patient
184 in the supine position. The examiner holds the elbow and wrist of the patient. Using the thigh,
185 the examiner depresses the scapular waist and internally rotates the shoulder, extends the
186 elbow, flexes the wrist, fingers and thumb^[16].

187 5. The upper limb tension test (ULTT 3) (neural tension of the ulnar) is performed
188 with the patient in the supine position, keeping the wrist of the patient extended and the
189 forearm supine, performing an elbow flexion. After positioning the patient, the therapist
190 performs a shoulder depression associated with an external rotation. Shoulder abduction is
191 added (so that the hand is close to the ear of the patient). In our assessment, we suppressed
192 lateral flexion of the cervical to isolate central pathologies. The test is considered positive
193 when the patient reports any discomfort/pain or when the physical therapist encounters
194 resistance to movement. When the patient has any of the reported symptoms, the test is

195 completed and the physiotherapist keeps the limb of the patient positioned in the range in
196 which pain or resistance to movement is reported to perform a goniometer measurement^[14].

197 The leprosy group was evaluated quarterly in 3 moments and the control group was
198 evaluated in a single moment. The application of the data collection instrument took 40 to 50
199 minutes and was performed by a single examiner.

200

201 **Data analysis**

202 • The Simplified Neurological Assessment was assigned with a value of 1 (without
203 changes) and 2 (with changes) for the upper and lower limbs. The same logic was applied for
204 the formulation of the SNA LLs column. We considered that the change in sensitivity in
205 hands decreased to ≥ 2 , corresponding to the 0.5g blue monofilament. The decrease in plantar
206 sensitivity was considered to be ≥ 3 , corresponding to the 2g purple monofilament. The
207 muscle strength domain was also considered to perform SNA grouping and was coded as
208 altered when muscle strength was less than or equal to 4, according to the Kendall scale^[15].
209 The palpation was marked as altered when there was pain, thickening, or both.

210 • We synthesize the results of the Neurodynamic Assessment in positive and
211 negative tests, considering the set of tests for the upper and lower limbs one apart to the other.

212 • The degree of physical disability of the WHO was classified as “*without disability*”
213 when it was Degree 0, and was grouped as “*disabled*” when its results were Degrees 1 or 2.

214 After tabulation of the data collected in this work, 2 analytical and statistical functions
215 were performed: descriptive and inferential. In a descriptive way, the profile of the studied
216 sample was drawn, considering the analyzed variables and their consequences, and the data
217 was replicated in an absolute and relative way.

218 In the inferential scope, the analysis of independence and prediction between
219 variables was drawn as a statistical objective. In addition, the Mann-Whitney U test and

220 Multivariate Linear Regression were used with the results of independence between the
221 proposed variables, taking into account the P-values (significance $P \leq 0.05$). All analyses were
222 obtained using the SPSS Statistics Software (Version 23) and were linked to the features of
223 the Excel tool (version 2016).

224 Statistical analysis and synthesis of the results were performed on a Venn-Euler
225 diagram. To perform the descriptive analysis and verify the association between SNA, DPD
226 and NDA results, EPI INFO 7.1 statistical software was used.

227 To validate the diagnostic tests, calculations of sensitivity, specificity, positive and
228 negative likelihood ratios were performed using the Virtual Health Library (*Biblioteca*
229 *Virtual de Saúde*, BVS) virtual calculator^[17]. Sensitivity, specificity and accuracy vary from
230 0-1^[18].

231 Likelihood ratios show the performance of a diagnostic test. The Positive Likelihood
232 Ratio (PLR) varies from 1 to infinity, the higher your result, the better the test. The Negative
233 Likelihood Ratio (NLR) varies from 1 to 0, the closer to 0, the better the test^[19].

234 **RESULTS**

235 In this study, 27 individuals diagnosed with leprosy who were notified in the years
236 2017 to 2019 participated (8 in the municipality of Votuporanga, 19 in the municipality of
237 São José do Rio Preto), in addition to 27 volunteers matched for age and sex in the control
238 group, totaling 54 people. Among the study group, 17 (63%) were male. The ages varied
239 between 23 and 88 years in the control group and between 23 and 87 years in the intervention
240 group, with a mean age of 53.1 (SD 17.6). The age median in the control group was 57 while
241 in the intervention group it was 55.

242 The age distribution was identical in the control and intervention groups due to the
243 pairing (n=54) (p-value 0.945). There was no difference in sex (p-value 1.00). In the
244 intervention group there were 19 (70.4%) active workers, in the control group it was 22
245 (81.5%) (p-value 0.344).

246 Regarding leprosy, 20 (74.1%) of the participants in the intervention group had the
247 dimorphous and Virchow's leprosy clinical forms, with multibacillary multidrug therapy
248 (74.1%) and still remained under drug treatment (74.1%). Seven (25.9%) patients had a
249 reaction phenomenon to leprosy.

250 The participants in the intervention group showed neurological changes in the upper
251 limbs, assessed by the three types of exams. The test that most captured data was the SNA
252 with 22 (81.5%) participants, followed by the Neurodynamic Assessment, where 20 (74.1%)
253 were altered, and the DPD showed deficiency in the hands of 16 (59.2%) individuals.

254 As assessing the lower limbs, it appears that in the intervention group the participants
255 showed neurological changes in the three assessments studied. Neurological changes were
256 more perceived by SNA, attested in 25 (92.6%) participants. The Degree of Physical
257 Disability showed a disability in 17 (62.9%) individuals. In the Neurodynamic Assessment,

258 11 (40.7%) showed alterations. In the control group, no neurological changes were identified
259 by the 3 instruments, confirming the reliability of the sample (Table 1).

260 In Figure 1, using the Venn-Euler diagram, it can be seen that 51.8% (14 of 27) of
261 patients were diagnosed with neural problems in the upper limbs using the three analysis
262 instruments. When we use only two associated assessments, the number of cases with
263 changes decreases. We also observed that the instruments individually captured different
264 people with problems, 2 (7.4%) with SNA and 2 with NDA; that is, 2 individuals that only
265 had their neural lesions identified because they passed through SNA and another 2 different
266 individuals only had neural injury identified because they were subjected to NDA.

267 In Figure 2, using the Venn-Euler diagram, it can be seen that 18.5% (5 of 27) of
268 patients were diagnosed with neural problems in the lower limbs using the three analysis
269 instruments. When using two instruments, SNA and NDA, the number of identified cases
270 remains with 5, (18.5%); using NDA and DPD it is 0 (0%), as they do not identify any
271 individual who is also not identified by SNA. Using the DPD instrument and the SNA
272 together identifies more individuals with neural lesions 12 (44.4%). We also observed that
273 the instruments individually captured different people with problems, 3 (11.1%) with SNA
274 and 1 (3.7%) with NDA; that is, three individuals only had their neural lesions identified
275 because they passed through SNA and the neural lesion of another different individual was
276 only identified because he was subjected to NDA.

277

278 **Sensitivity, specificity, positive and negative likelihood ratio**

279 To define the characteristics of the tests as a diagnosis, we used the concepts of
280 sensitivity, specificity and positive and negative likelihood ratios considering the ULs and
281 the LLs separately, based on the distribution of the test results, in order to provide evidence
282 on which clinical practices can be based. (Table 2)

283 Our sample tells us that the instruments used are specific because the 3 assessments
284 obtained a value equal to 1 in both the upper limbs and lower limbs, and that they hardly
285 produce false positives, since the positive likelihood ratio tended to infinity in the 3
286 assessment instruments^[19].

287 Considering the sensitivity, we saw that SNA is the most sensitive test to assess the
288 upper limbs in individuals with leprosy, as it had a value of 0.81, followed by the NDA with
289 0.74. The DPD is considered least sensitive, with a value that was equal to 0.59^[18]. In LLs,
290 SNA remains as the most sensible over other assessment instruments, with 0.92. NDA was
291 not a tool as sensitive for LLs as it was for ULs because we obtained a sensitivity value equal
292 to 0.41. DPD obtained a better sensitivity, with 0.63^[18].

293 The best accuracy in ULs was obtained by SNA (0.90), followed by NDA (with 0.87)
294 and DPD (with 0.80), whereas in LLs, the accuracy of SNA was 0.96, followed by DPD,
295 with 0.81, and NDA, with 0.70^[18].

296 According to the Negative Likelihood Ratio (NLR) in ULs, SNA obtained the best
297 value among the evaluations, with 0.18, while the value in the NDA and DPD was 0.26 and
298 0.40, respectively, showing that false negatives can occur more frequently in the NDA, and
299 could be still larger in the DPD. In LLs, the NLR in the SNA was 0.07, meaning that it is
300 difficult for the SNA to produce a false negative; however, the NDA can produce false
301 negatives because the NLR was equal to 0.60; the DPD also could report no deficiency while
302 in fact there is already a neural alteration because the NLR was equal to 0.37^[19].

303

304 **Degree of hand and foot disabilities compared to the Simplified Neurological** 305 **Assessment and Neurodynamic Assessment of upper and lower limbs**

306 The WHO Disability Degree indicator of the hands shows agreement in 21 (77.8%)
307 of the cases that were assessed by SNA (P-value = 0.010). It should be noted that the SNA

308 made the diagnosis of neural injury in 6 (22.3%) cases that, according to the DPD, did not
309 have physical disability (degree zero of physical disability).

310 Regarding the association of the degree of hand impairment with the Neurodynamic
311 Assessment in 51.8% (n=14) of the patients evaluated there were agreed positive results; in
312 18.5% (n=5) there were agreed negative results. The results differed in eight participants,
313 with the Neurodynamic Assessment more frequently capturing neural changes (n=6/22.2%)
314 than the Degree of Physical Disability (n=2/7.4%). The association was not significant (p-
315 value=0.143).

316 The comparison between the degree of disability of the feet and the SNA of the lower
317 limbs was acceptable in 62.9% (n=17) of the cases but diverged in 29.6% (n=8) cases,
318 exposing a greater sensitivity of the SNA in showing the neural damage, despite the
319 association not showing statistical significance (p-value=0.060).

320 Verifying the degree of disability of the feet and the Neurodynamic Assessment of
321 the lower limbs showed agreement of positive results in 18.5% (n=5) of the patients evaluated
322 and in 14.8% (n=4) of the negative results. In eighteen participants, the results differed; the
323 Degree of Physical Disability of the feet more frequently captured neural changes
324 (n=12/44.4%) than the Neurodynamic Assessment (n=6/22.2%). The association was not
325 significant (p-value=0.125). (Table 3)

326

327 **Simplified Neurological Assessment compared to Neurodynamic Assessment in the** 328 **Upper and Lower Limbs**

329 By checking the Simplified Neurological Assessment and the Neurodynamic
330 Assessment in the ULs, we found agreement on the positive results in 66.7% (n=18) of the
331 cases with neurological changes and in 11.1% (n=3) of the cases without changes with
332 negative tests. There was disagreement in six individuals. The SNA was more effective in

333 verifying the neurological changes of the upper limbs in 14.8% (n=4) cases while the
334 Neurodynamic Assessment identified it in 7.4% (n=2) cases.

335 The association between Simplified Neurological Assessment and the Neurodynamic
336 Assessment of lower limbs showed agreement on positive results in 37% (n=10) of the
337 patients evaluated and in 3.7% (n=1) of the negative results. In sixteen participants, the results
338 differed, the SNA of LLs more frequently captured neural changes (n=15/55.5%) than the
339 Neurodynamic Assessment of the lower limbs (n=1/3.7%). The association was not
340 significant (p-value=0.786). (Table 4)

341 **DISCUSSION**

342 With this study we hoped to identify an evaluation protocol that used only human
343 resources for its execution, facilitating the identification of neural lesions in leprosy
344 combined with the daily practice of physical therapists who are not involved in the
345 management of leprosy, but routinely use Neurodynamic Assessment. In this way, more
346 suspicions and diagnoses of the disease could be made and would help in cases that present
347 themselves as purely neural. Concerning leprosy, it is important that not only the physician
348 suspects the disease, but any health professional.

349 There was no statistical difference in relation to sex, age and occupation in the two
350 groups studied, since the pairing was performed to avoid the effect of age and sex, two
351 recognized confounding factors for the results^[20,21], so a comparison was made between
352 groups, showing similarity and equal care between them^[22,23].

353 In the intervention group, men, active, with an average age of 53.09 years and
354 multibacillary disease were more frequent, as happened in Santarém, where they had ages
355 above 51 years old^[24], being one of the sociodemographic factors that were associated with
356 the installation of disabilities^[25].

357 Regarding neurological tests, the one that most captured neural alterations was the
358 SNA in both upper limbs and lower limbs, highlighting the importance of the process of
359 identifying the degree of disabilities through SNA, at the beginning of treatment and after
360 discharge^[26]. Studies show worsening of physical disabilities during treatment, mainly in the
361 multibacillary form, with the lower limbs being the segments that show the most significant
362 degree of disability evolution, justifying the imperative need for a more careful monitoring
363 of these cases through routine assessments and interventions^[27].

364 In the univariate and multivariate analysis, there is agreement of the result found in
365 the DPD with the SNA in the upper limbs, but the SNA detects neural lesions more

366 sensitively. Since disability is only considered when sensitivity is decreased beyond purple
367 monofilament and/or muscle strength is less than 5, DPD does not detect the subtle changes
368 that suggest neural distress, and we emphasize that the SNA made the diagnosis of neural
369 injury in 6 (22.3%) of the cases while, according to the DPD, those cases did not yet present
370 disabilities, showing the importance of using and applying SNA.

371 The degree of physical disability was an innovative measure to gradually quantify
372 physical disability in an index, but with the increasingly early diagnosis of neural damage, it
373 was necessary to improve the assessment instruments. Due to the change in the profile of
374 patients today, these instruments need to be more sensitive to subtle changes that neurological
375 changes show us over the course of the disease, so SNA is more sensitive in detecting
376 neurological changes and their influences on socioeconomic and emotional aspects^[28].

377 The DPD is recommended at the beginning of treatment and at discharge, but when
378 the patient shows a slight improvement, there is no variation in the degree of disability and
379 the services are unable to assess whether the actions developed are actually being
380 effective^[29]. It must be considered that when the case is carefully evaluated and the results
381 of the exams recorded in the SNA protocol, the diagnosis of deficiencies in the eyes, hands
382 and feet is more accurate than when the deficiency is identified using the framework “WHO
383 degree of physical disability”^[26].

384 As an indicator, there is a fragile and subjective comparison of the DPD with the
385 limitation of activities, and the social participation of the patients is not included in its results.
386 An adaptation of the indicator is necessary to develop a more current classification, based on
387 a more comprehensive concept of disability, as is done by the International Classification of
388 Functioning (ICF)^[30].

389 Nerve damage is associated with physical disabilities. Thus, regular monitoring of
390 nerve function, through SNA, combined with adequate clinical management of neuritis,
391 neuropathies and leprosy reactions, are effective strategies to prevent it^[31].

392 In the univariate analysis, as well as in the multivariate, of ULs and LLs, DPD and
393 NDA, despite their results being relative to neural injury concordance in some cases, were
394 not statistically significant. The NDA seems to identify 75% more injuries in the upper limbs
395 than the DPD, and DPD seems to identify 50% more injuries in the lower limbs than the
396 NDA.

397 Considering leprosy and NDA, a study of ULs found a positive NDA, mainly
398 affecting those with a degree of physical disability level 2. Of these, they presented a decrease
399 in the ROM of elbow flexion in the ulnar neural tension test (ULTT3) on both sides when
400 compared to control group^[14].

401 Leprosy patients test positive when submitted to Neurodynamic Assessment of lower
402 limbs^[23]. But, even when the tests do not reproduce the symptoms in the affected nerves,
403 characterizing negative tests, studies suggest that a neuropathy cannot be ruled out yet, this
404 can mean a more severe lesion with demyelination of the fibres^[33] (as occurred in degree 2
405 patients that tested negative in the lower limbs in our analysis), producing a possible false
406 negative result^[18], thus explaining the low sensitivity of the NDA in lower limbs, because
407 low sensitivity produces more false negative results^[18].

408 Both in the univariate and multivariate analysis of ULs and LLs, when comparing the
409 SNA with the NDA, we note that the SNA identifies the neural lesion earlier than the NDA.

410 According to the evidence available in 2019, it is suggested that neurodynamic tests
411 should not be used in isolation, as a single test, to diagnose neural distress of the median
412 nerve. They should be interpreted in the context of a loss of function tests of small fibres in
413 a domain^[32]. Combining anamnesis and clinical history is an important tool to make the

414 differential diagnosis, where the combination of negative neurodynamic test results could be
415 used to rule out a disorder in the peripheral nerves; with limited evidence, they are relevant
416 in cervical radiculopathies^[33].

417 The need for adaptation of the peripheral nervous system (PNS) in the face of
418 mechanical stress, stretching, slips, changes in its diameter and compressions is notorious. If
419 this dynamic protection mechanism fails, the PNS is vulnerable to edema, ischemia, fibrosis
420 and hypoxia, which are the causes of neural changes^[34].

421 In this sense, the scientific community highlights the need for more possibilities for
422 neural injury investigations in leprosy, in order to diagnose and monitor the neurological
423 changes caused by it. A study in Nigeria points out that 50% of patients who complete
424 treatment already had neurological changes before diagnosis, according to the EHF score,
425 but 90%, when receiving assistance and monitoring of injuries, end treatment with less
426 disability^[35]. Neural damage needs to be identified early and current leprosy control efforts
427 must be intensified to ensure immediate treatment in order to reduce the burden of the
428 disease, including deficiencies in individuals and the community. When using EHF, greater
429 sensitivity is offered in the evaluation compared to DPD^[29]. Physical disabilities were
430 diagnosed in 41% of the individuals. The EHF score showed overlapping of impairments in
431 the examined segments and proved to be more appropriate than the DPD classification system
432 to describe the extent of the physical disabilities in the patients^[36].

433 In our study, neurodynamic tests were positive in 2 (7.4%) individuals while there
434 were still no changes in SNA and later these changes appeared, which makes us think of the
435 association of assessments as a way to complement the diagnosis and monitoring of neural
436 changes. This would make professionals, when applying NDA, be able to suspect neural
437 injury caused by leprosy and minimally perform other evaluations, making a more accurate
438 investigation or even referring it to a specialist in the area.

439 Therefore, a need to create an assessment (validated or not) is necessary so that we
440 can, through an indicator, reveal the neural lesion more precociously, given that 95% of
441 patients have neurological changes, with musculoskeletal symptoms, which interfere in their
442 functional capacities, causing difficulties in performing their activities of daily living and
443 work when compared to those who have no symptoms. However, the presence of disability
444 did not prevent or limit them from performing these activities. Even with pain, paresthesia,
445 decreased strength and other injuries, they still perform their activities^[37].

446 **Conclusions**

447 We conclude that the 3 assessment instruments are specific and that these assessments
448 can and should be used in combination to expand the monitoring of neural lesions in leprosy,
449 as there are changes that are not perceptible with one instrument but can be confirmed by
450 another.

451 The Simplified Neurological Assessment (SNA) is the most sensitive instrument,
452 with greater accuracy and it is unlikely to produce a false negative both in the assessments
453 of the upper limbs and lower limbs. The Neurodynamic Assessment (NDA) is the second
454 most sensitive instrument for assessing ULs, followed by the Degree of Physical Disability
455 (DPD). In LLs, the second most sensitive instrument is DPD, followed by NDA.

456 Both NDA and DPD can produce false negative results more frequently than SNA,
457 that is, reporting that nerves are healthy while in reality they already have existing
458 neurological changes, implying that some individuals may not receive the proper treatment
459 as early as possible.

460 The negative likelihood ratio confirms that the DPD produces more false negatives
461 than SNA, so when the DPD tells us that there are no neurological changes yet, they may
462 already be present at a more subtle level, so we suggest that the DPD always be performed
463 after the results of the SNA and not determining the DPD using only the table that helps in
464 the summary of the SNA data proposed by the guidelines, which considers visible
465 deficiencies such as a Degree of Physical Disability Level 2 (DPD 2) or a barely visible
466 Degree of Physical Disability level 1 (DPD 1), since neurological alterations are thus
467 underestimated.

468 Greater coverage is achieved, for the early identification of neural injuries, by
469 applying the 3 assessments studied in this research, opting for SNA, if you choose only one,

470 as it was the most sensitive and accurate instrument for identifying neural injuries in isolation,
471 in addition to having the least negative likelihood ratio.

472 NDA does not establish a relationship of dependency with DPD instruments, nor with
473 SNA; in its application to investigate neural injury in people who have leprosy, it does not
474 prove to be such a sensitive tool in isolation, but when associated with clinical anamnesis
475 and evaluations already used, DPD and SNA, it facilitates diagnosis, impacting the suspicion
476 of new cases of the disease.

477 The association of leprosy and neurodynamics issues alerts professionals not involved
478 with leprosy to suspect leprosy neuropathy when they find a positive neurodynamic test in
479 their clinical practice. Neurodynamic tests were positive in 7.4% of individuals while there
480 were still no changes in SNA and later these changes appeared. Future studies could clarify
481 whether NDA can reveal neural injury earlier.

482 **REFERENCES**

- 483 1. Boletim. Epidemiológico. Situação epidemiológica e estratégias. Boletim
484 Epidemiológico. Secretaria de Vigilância em Saúde. Ministério da Saúde. 2. ed. Brasília:
485 Ministério da Saúde; 2014. 52 p.
- 486 2. Secretaria de Vigilância em Saúde. Ministério da Saúde. Boletim Epidemiológico.
487 Hanseníase 2020; Supl. Jan. 2020.
- 488 3. World Health Organization. Global Leprosy Strategy 2016-2020: Accelerating
489 towards a leprosy-free world. 2016.
- 490 4. Guidelines for the diagnosis, treatment and prevention of leprosy. New Delhi: World
491 Health Organization, Regional Office for South-East Asia. 2018
- 492 5. Freitas RCSD, Pereira, CAZ, Muri NT, Franzon VAZ, Fatuch CAC. Primary Neural
493 Leprosy mimicking rheumatological disorders. Revista da Associação Médica Brasileira,
494 2019; 65(6):767-770.
- 495 6. Santos DFD, Mendonça MR, Antunes DE, Sabino EFP, Pereira RC, Goulart LR,
496 Goulart IMB. Revisiting primary neural leprosy: Clinical, serological, molecular, and
497 neurophysiological aspects. PLOS Neglected Tropical Diseases 2017;11(11)
- 498 7. Ministério da Saúde (Brazilian Ministry of Health). Secretaria de Vigilância em
499 Saúde, Departamento de Vigilância das Doenças Transmissíveis. Diretrizes para
500 vigilância, atenção e eliminação da hanseníase como problema de saúde pública. Brasília:
501 Brazilian Ministry of Health. 2016.
- 502 8. Carter GT, Weiss MD. Diagnosis and treatment of work-related proximal median
503 and radial nerve entrapment. Physical Medicine and Rehabilitation Clinics. 2015;
504 26(3):539-549.
- 505 9. Karmakar M, Joshua JM. Changes in plantar load distribution and gait pattern
506 following foot drop correction in leprosy affected patients. LeprRev. 2015; 86: 213–219
- 507 10. Rohatgi S, Naveen S, Salunke P, Someshwar S, Rajiv HJ, Joshi R. The story of a
508 deformed leprous foot. LeprRev. 2016; 87: 104–108
- 509 11. Júnior LGC, Machado GB, & Faria TA. (2015). Reação hansênica tipo dois em
510 paciente multibacilar, forma Virchowiana, em vigência de tratamento: relato de
511 caso. Revista de Medicina, 94(3), 197-200.
- 512 12. Ministério da Saúde (Brazilian Ministry of Health), Office of the Minister.
513 Ordinance No. 149 of February 3, 2016. Approves the Guidelines for Surveillance,
514 Attention and Elimination of Leprosy as a Public Health Problem, with the purpose of
515 guiding managers and professionals of health services [Internet]. Brasília: Brazilian
516 Ministry of Health; 2016 [cited 2020 Sept 01]. Available from:
517 http://bvsmms.saude.gov.br/bvs/saudelegis/gm/2016/prt0149_04022016.html
- 518 13. Shacklock M. Neurodynamics. Physiotherapy. 1995; 81(1): 9-16.

- 519 14. . Scheibe D, de Oliveira JFP, Gonçalves SB, Gomes ARS, de Macedo ACB.
520 Mensuração do ângulo articular do cotovelo no teste de tensão neural em indivíduos com
521 hanseníase. *Fisioterapia e Pesquisa*. 2012;19(2):165-170
- 522 15. Brazil. Ministério da Saúde (Ministry of Health). Secretariat of Health Surveillance.
523 Department of Surveillance of Transmissible Diseases. Guia prático sobre a hanseníase
524 [recurso eletrônico] / Ministério da Saúde, Secretaria de Vigilância em Saúde,
525 Departamento de Vigilância das Doenças Transmissíveis. – Brasília: Ministério da Saúde,
526 2017. 68 p.: il.
- 527 16. Butler DS. Mobilização do sistema nervoso. Manole: Barueri (SP). 2003
- 528 17. Biblioteca Virtual em Saúde – BVS (Virtual Health Library), Atenção Primária em
529 Saúde. Programa nacional Rede Telessaúde Brasil, Calculadoras, abordagem diagnóstica.
530 [cited 2020 Sep 1]. Available from: <https://aps.bvs.br/apps/calculadoras/?page=1>.
- 531 18. Ferreira JC, Patino CM. Understanding diagnostic tests. Part 1. *J Bras Pneumol*. 2017
532 Sep-Oct;43(5):330. doi: 10.1590/S1806-37562017000000330. PMID: 29160379;
533 PMCID: PMC5790651.
- 534 19. Ferreira Juliana Carvalho, Patino Cecília Maria. Entendendo os testes diagnósticos.
535 Parte 3. *J. bras. pneumol*. [Internet]. 2018 Feb [cited 2020 Aug 18]; 44(1): 4-4. Available
536 from: [http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1806-](http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1806-37132018000100004)
537 [37132018000100004 &lng=en. https://doi.org/10.1590/s1806-37562018000000017](https://doi.org/10.1590/s1806-37562018000000017).
- 538 20. Caminha MDFC, Cruz RDSBL, Acioly VMCD, Nascimento RRD, Azevedo
539 PTÁCC, Lira PICD, Batista Filho M. Fatores de risco para a não amamentação: um estudo
540 caso-controle. *Revista Brasileira de Saúde Materno Infantil*. 2015; 2:193-199.
- 541 21. Boas práticas clínicas. Documento das Américas. Organização Pan-americana de
542 Saúde. Organização Mundial de Saúde, Rede Pan-americana para Harmonização da
543 Regulamentação Farmacêutica Clínicas. 2005 [cited 2020 May 25].
- 544 22. Guyatt GH, Sackett DL, Cook DJ, Guyatt G, Bass E, Brill-Edwards P, Haynes B.
545 Users' guides to the medical literature: II. How to use an article about therapy or
546 prevention A. Are the results of the study valid? *Jama*. 1993;21:270.
- 547 23. Esse estudo é válido? PEDro Physiotherapy evidence database. 2020; [cited 2020
548 may 25]. Available from: <https://www.pedro.org.au/portuguese/tutorial/is-the-trial-valid/>
- 549 24. de Macêdo Basso ME, da Silva RLF. Perfil clínico-epidemiológico de pacientes
550 acometidos pela hanseníase atendidos em uma unidade de referência. *Revista da*
551 *Sociedade Brasileira de Clínica Médica*. 2017;1:27-32.
- 552 25. da Silva JSR, Palmeira IP, Sá AMM, Nogueira LMV, Ferreira AMR. Fatores
553 sociodemográficos associados ao grau de incapacidade física na hanseníase. *Revista*
554 *Cuidarte*. 2018;9(3): 2338-2348.
- 555 26. Finez MA, Salotti SRA. Identificação do grau de incapacidades em pacientes
556 portadores de hanseníase através da avaliação neurológica simplificada. *J Health Sci*
557 *Inst*. 2011; 29(3):171-5.

- 558 27. Vieira CSCA, Mariano MLL, Silva EMA. Prevalência das deficiências físicas da
559 hanseníase após alta medicamentosa em municípios que alcançaram a meta de
560 eliminação. *Hansen Int.* 2016. 41 (1-2): p. 46-54.
- 561 28. Santos AR, Ignotti E. Prevenção de incapacidade física por hanseníase no Brasil:
562 Análise histórica. *Cien Saude Colet [journal on the Internet]* (2019/Jan). [cited 2020 may
563 23]. Available from: [http://www.cienciaesaudecoletiva.com.br/artigos/prevencao-de-](http://www.cienciaesaudecoletiva.com.br/artigos/prevencao-de-incapacidade-fisica-por-hansenia-no-brasil-analise-historica/17077?id=17077)
564 [incapacidade-fisica-por-hansenia-no-brasil-analise-historica/17077?id=17077](http://www.cienciaesaudecoletiva.com.br/artigos/prevencao-de-incapacidade-fisica-por-hansenia-no-brasil-analise-historica/17077?id=17077)
- 565 29. Nardi SMT, Cruz LPD, Pedro HDSP, Marciano LHSC, Paschoal VDA. Avaliação
566 das deficiências físicas em pessoas com hanseníase empregando dois indicadores: grau
567 de incapacidades e Eyes-Hands-Feet. *Hansenologia Internationalis (Online)*. 2011;36(2):
568 09-15.
- 569 30. De Souza VTC, Junior WMS, De Jesus AMR, De Oliveira DT, Raptis HA, De Freitas
570 PHL, Secheinberg S. Is the WHO disability grading system for leprosy related to the level
571 of functional activity and social participation. *Lepr Rev.* 2016;87(2): 191-201.
- 572 31. Silva JSRD, Palmeira IP, Sá AMM, Nogueira LMV, Ferreira AMR. Variáveis
573 clínicas associadas ao grau de incapacidade física na hanseníase. *Revista Cuidarte.* 2019;
574 10(1): Jan-Apr.
- 575 32. Thoomes EJ, Van Geest S, Van Der Windt DA, Falla D, Verhagen AP, Koes BW,
576 Vleggeert-Lankamp CL. Value of physical tests in diagnosing cervical radiculopathy: a
577 systematic review. *The SpineJournal.* 2018; 1:179-189.
- 578 33. Koulidis K, Veremis Y, Anderson C, Heneghan NR. Diagnostic accuracy of upper
579 limb neurodynamic tests for the assessment of peripheral neuropathic pain: a systematic
580 review. *Musculoskelet Sci Pract.* 2019 Apr;40:21-33.
- 581 34. Ellis RF, Hing WA. Neural mobilization: a systematic review of randomized
582 controlled trials with an analysis of therapeutic efficacy. *Journal of manual &*
583 *manipulative therapy*, 2008. 16(1): 8-22.
- 584 35. Onyeonoro UU, Aguocha GU, Madukwe SO, Nwokeukwu HI, Nwamoh UN,
585 Aguocha BU. Pattern of disabilities among leprosy patients in Abia State, Nigeria—a
586 retrospective review. *Indian J Lepr.* 2016; 88(1), 21-28.
- 587 36. Raposo MT, Caminha AVDQ, Heukelbach J, Sánchez-González MÁ, Medeiros
588 JLAD, Nemes MIB. Assessment of physical impairments in leprosy patients: a
589 comparison between the world health organization (WHO) disability grade and the eye-
590 hand-foot score. *Revista do Instituto de Medicina Tropical de São Paulo.* 2011; 53(2): 77-
591 81.
- 592 37. Do Prado GD, Prado RB, Marciano LH, Nardi SM, Cordeiro JA., Monteiro HL.
593 WHO disability grade does not influence physical activity in Brazilian leprosy
594 patients. *Lepr Rev.* 2011. 82(3):270-278.
595

596 **Table 1.** Distribution of the results of the Simplified Neurological Assessment, degree of
597 hand and foot disabilities, neurodynamic test of the upper and lower limbs in the
598 intervention group. (N=27)
599

TESTS	RESULTS	LIMBS							
		Intervention Group				Control Group			
		Upper		Lower		Upper		Lower	
		n	%	n	%	n	%	n	%
Simplified Neurological Assessment	No alteration	5	18.52	2	7.41	27	100	27	100
	Alteration	22	81.48	25	92.59	0	0	0	0
Degree of Physical Disability	No disability (Degree zero)	11	40.74	10	37.04	27	100	27	100
	Disability (Degree I and II)	16	59.26	17	62.96	0	0	0	0
Neurodynamic Assessment	Negative	7	25.93	16	59.26	27	100	27	100
	Positive	20	74.07	11	40.74	0	0	0	0

600

601 **Table 2.** Measures of sensitivity, specificity, accuracy, positive and negative likelihood
602 ratios for Simplified Neurological Assessment, Neurodynamic Assessment (NDA) and
603 Degree of Physical Disability (DPD) in the upper and lower limbs
604

605

Measures	ULs	SNA Test	NDA Test	DPD Test
0-1	Sensitivity	0.81	0.74	0.59
	Specificity	1	1	1
	Accuracy	0.90	0.87	0.80
1 to 0	NLR	0.18	0.26	0.41
1 to infinity	PLR	Infinite	Infinite	Infinite
Measures	LLs	SNA Test	NDA Test	DPD Test
0-1	Sensitivity	0.92	0.41	0.63
	Specificity	1	1	1
	Accuracy	0.96	0.70	0.81
1 to 0	NLR	0.07	0.59	0.37
1 to infinity	PLR	Infinite	Infinite	Infinite

606 **Caption:** SNA: Simplified neurological assessment; NDA: Neurodynamic Assessment;
607 DPD: Degree of Physical Disability; ULs: Upper limbs; LLs: Lower limbs NLR: negative
608 likelihood ratio; PLR: positive likelihood ratio⁴³
609

610 **Table 3.** Degree of hand and foot disabilities compared to Simplified Neurological
611 Assessment and Neurodynamic Assessment in upper limbs and lower limbs when applied
612 to the intervention group. (n=27)
613

	Simplified Neurological Assessment	DEGREE OF HANDS DISABILITIES				P-value
		No Disability		Disability		
		n	%	n	%	
ULs	No alteration	5	18.51	0	0.00	0.010
	Alteration	6	22.33	16	59.25	
	Neurodynamic Assessment	No Disability		Disability		0.143
		n	%	n	%	
Negative		5	18.51	2	7.41	
Positive	6	22.22	14	51.85		

	Simplified Neurological Assessment	DEGREE OF FEET DISABILITY				P-value
		No Disability		Disability		
		n	%	N	%	
LLs	No alteration	2	7.41	0	0.00	0.060
	Alteration	8	29.62	17	62.96	
	Neurodynamic Assessment	No Disability		Disability		0.125
		n	%	n	%	
Negative		4	14.81	12	44.44	
Positive	6	22.22	5	18.51		


614

615 **Table 4.** Simplified Neurological Assessment compared to Neurodynamic Assessment,
616 in the upper and lower limbs, when applied to the intervention group.
617

	NEURODYNAMIC ASSESSMENT	SIMPLIFIED NEUROLOGICAL ASSESSMENT				p-value
		No Alteration		Alteration		
		N	%	n	%	
Upper limbs	Negative	3	11.11	4	14.81	0.059
	Positive	2	7.41	18	66.67	
Lower limbs	Negative	1	3.70	15	55.56	0.786
	Positive	1	3.70	10	37.04	

618

619 **Figure 1.** Intersection of three assessments used to check upper limbs (ULs) neurological
620 injuries of individuals with leprosy using the Venn-Euler Diagram.
621




622
623

624 **Caption.** SNA: Simplified Neurological Assessment; DPD: Degree of Physical
625 Disability; NDA: Neurodynamic Assessment. A = individuals captured only through
626 SNA, B = individuals captured only through NDA, C = individuals captured only through
627 DPD

628

629 **Figure 2.** Intersection of the results obtained from the three assessments used to verify
630 neurological injuries in the lower limbs (LLs) of individuals with leprosy



631
632
633
634
635
636

Caption. SNA: Simplified Neurological Assessment; DPD: Degree of Physical Disability; NDA: Neurodynamic Assessment. A = individuals captured only through SNA, B = individuals captured only through NDA, C = individuals captured only through DPD.